Improved clinical outcomes during long-term osilodrostat treatment of Cushing’s disease with LNSC and UFC normalization

Abstract

Abstract Purpose To assess whether simultaneous normalization of late-night salivary cortisol (LNSC) and mean urinary free cortisol (mUFC) in patients with Cushing’s disease treated with osilodrostat is associated with better clinical outcomes than control of mUFC or LNSC alone. Methods Pooled data from two Phase III osilodrostat studies (LINC 3 and LINC 4) were analyzed. Both comprised a 48-week core phase and an optional open-label extension. Changes in cardiovascular/metabolic-related parameters, physical manifestations of hypercortisolism, and quality of life (QoL) were evaluated across the following patient subgroups: both LNSC and mUFC controlled, only mUFC controlled, only LNSC controlled, and neither controlled. Results Of 160 patients included in the analysis, 85.0% had both LNSC and mUFC uncontrolled at baseline. At week 72, 48.6% of patients had both LNSC and mUFC controlled; these patients generally exhibited greater improvements in cardiovascular/metabolic-related parameters than those with only mUFC controlled or both LNSC and mUFC uncontrolled: systolic/diastolic blood pressure, –7.4%/–4.9%, –6.0%/–5.5%, and 2.3%/0.8%, respectively; fasting plasma glucose, –5.0%, –4.8%, and 1.9%; glycated hemoglobin, –5.1%, –4.8%, and –1.3%. Weight, waist circumference, and body mass index improved with control of LNSC and/or mUFC; physical manifestations of hypercortisolism generally improved regardless of LNSC/mUFC control. Patients with both LNSC and mUFC controlled or only mUFC controlled had the greatest improvement from baseline to week 72 in QoL. Conclusions In osilodrostat-treated patients with Cushing’s disease, normalization of LNSC and mUFC led to improvements in long-term outcomes, indicating that treatment should aim for normalization of both parameters for optimal patient outcomes.